期刊
BIOORGANIC CHEMISTRY
卷 67, 期 -, 页码 84-94出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bioorg.2016.06.001
关键词
Acridine-chromenone; Alzheimer's disease; Anti-cholinesterase; Docking study; Neuroprotective activity; Quinoline-chromenone; beta-Secretase inhibitor
资金
- Research Council of Tehran University of Medical Sciences [94-03-33-30167]
A novel series of acridine-chromenone and quinoline-chromenone hybrids were designed, synthesized, and evaluated as anti-Alzheimer's agents. All synthesized compounds were evaluated as cholinesterases (ChEs) inhibitors and among them, 7-(4-(6-chloro-2,3-dihydro-1H-cyclopenta[b]quinolin-9-ylamino)phe noxy)-4-methyl-2H-chromen-2-one (8e) exhibited the most potent anti-acetylcholinesterase (AChE) inhibitory activity (IC50 = 16.17 mu M) comparing with rivastigmine (IC50 = 11.07 mu M) as the reference drug. Also, compound 8e was assessed for its beta-secretase (BACE1) inhibitory and neuroprotective activities which demonstrated satisfactory results. It should be noted that both kinetic study on the inhibition of AChE and molecular modeling revealed that compound 8e interacted simultaneously with both the catalytic active site (CAS) and peripheral anionic site (PAS) of AChE. (C) 2016 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据